GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Euroespes SA (XMAD:EEP) » Definitions » Cash And Cash Equivalents

Euroespes (XMAD:EEP) Cash And Cash Equivalents : €0.97 Mil (As of Dec. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Euroespes Cash And Cash Equivalents?

Euroespes's quarterly cash and cash equivalents declined from Dec. 2021 (€1.97 Mil) to Jun. 2022 (€1.54 Mil) but then stayed the same from Jun. 2022 (€1.54 Mil) to Dec. 2022 (€0.97 Mil).

Euroespes's annual cash and cash equivalents declined from Dec. 2020 (€2.22 Mil) to Dec. 2021 (€1.97 Mil) and declined from Dec. 2021 (€1.97 Mil) to Dec. 2022 (€0.97 Mil).


Euroespes Cash And Cash Equivalents Historical Data

The historical data trend for Euroespes's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Euroespes Cash And Cash Equivalents Chart

Euroespes Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.43 2.34 2.22 1.97 0.97

Euroespes Semi-Annual Data
Dec12 Jun13 Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.22 1.92 1.97 1.54 0.97

Euroespes Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Euroespes  (XMAD:EEP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Euroespes Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Euroespes's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Euroespes Business Description

Traded in Other Exchanges
N/A
Address
Santa Marta de Babio, Bergondo, La Coruna, ESP, 15165
Euroespes SA is a biomedical research center offering medical, research, medical informatics and bioinformatics services. It offers medicine and personalized treatment for central nervous system disorders and researches genomic medicine. Other services offered by the company include genomics, digital diagnosis, diagnostic imaging, neuro-psychology, neuro-ophthalmology, nursing, epigenetics, clinical analysis and otorhinolaryngology.